Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions

Background This study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and septic shock diagnosed according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Methods Serum levels of IL-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC infectious diseases Jg. 19; H. 1; S. 968 - 11
Hauptverfasser:	Song, Juhyun, Park, Dae Won, Moon, Sungwoo, Cho, Han-Jin, Park, Jong Hak, Seok, Hyeri, Choi, Won Seok
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 12.11.2019 BioMed Central Ltd BMC
Schlagworte:	Adult Aged Aged, 80 and over Area Under Curve Bacterial and fungal diseases Biomarkers - blood C-Reactive Protein - analysis Case-Control Studies Emergency department Female Hospital admission and discharge Humans Infection Infectious Diseases Interleukin-6 Interleukin-6 - blood Interleukins Internal Medicine Male Medical Microbiology Medical research Medicine Medicine & Public Health Middle Aged Mortality Parasitology Pentraxin 3 Procalcitonin Procalcitonin - blood Prognosis Research Article Risk Factors ROC Curve Sensitivity and Specificity Sepsis Sepsis - diagnosis Sepsis - mortality Sepsis - pathology Septic shock Serum Amyloid P-Component - analysis Severity of Illness Index Shock Shock, Septic - diagnosis Shock, Septic - mortality Shock, Septic - pathology Tropical Medicine Sepsis Septic shock Emergency department Pentraxin 3 Procalcitonin Interleukin-6
ISSN:	1471-2334, 1471-2334
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Background This study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and septic shock diagnosed according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Methods Serum levels of IL-6, PTX3, and PCT were measured in 142 enrolled subjects (51 with sepsis, 46 with septic shock, and 45 as controls). Follow-up IL-6 and PTX3 levels were measured in patients with initial septic shock within 24 h of hospital discharge. Optimal cut-off values were determined for sepsis and septic shock, and prognostic values were evaluated. Results Serum IL-6 levels could discriminate sepsis (area under the curve [AUC], 0.83–0.94, P < 0.001; cut-off value, 52.60 pg/mL, 80.4% sensitivity, 88.9% specificity) from controls and could distinguish septic shock (AUC, 0.71–0.89; cut-off value, 348.92 pg/mL, 76.1% sensitivity, 78.4% specificity) from sepsis. Twenty-eight-day mortality was significantly higher in the group with high IL-6 (≥ 348.92 pg/mL) than in the group with low IL-6 (< 348.92 pg/mL) ( P = 0.008). IL-6 was an independent risk factor for 28-day mortality among overall patients (hazard ratio, 1.0004; 95% confidence interval, 1.0003–1.0005; p = 0.024). In septic shock patients, both the initial and follow-up PTX3 levels were consistently significantly higher in patients who died than in those who recovered (initial p = 0.004; follow-up P < 0.001). Conclusions The diagnostic and prognostic value of IL-6 was superior to those of PTX3 and PCT for sepsis and septic shock.
AbstractList	Background This study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and septic shock diagnosed according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Methods Serum levels of IL-6, PTX3, and PCT were measured in 142 enrolled subjects (51 with sepsis, 46 with septic shock, and 45 as controls). Follow-up IL-6 and PTX3 levels were measured in patients with initial septic shock within 24 h of hospital discharge. Optimal cut-off values were determined for sepsis and septic shock, and prognostic values were evaluated. Results Serum IL-6 levels could discriminate sepsis (area under the curve [AUC], 0.83–0.94, P < 0.001; cut-off value, 52.60 pg/mL, 80.4% sensitivity, 88.9% specificity) from controls and could distinguish septic shock (AUC, 0.71–0.89; cut-off value, 348.92 pg/mL, 76.1% sensitivity, 78.4% specificity) from sepsis. Twenty-eight-day mortality was significantly higher in the group with high IL-6 (≥ 348.92 pg/mL) than in the group with low IL-6 (< 348.92 pg/mL) ( P = 0.008). IL-6 was an independent risk factor for 28-day mortality among overall patients (hazard ratio, 1.0004; 95% confidence interval, 1.0003–1.0005; p = 0.024). In septic shock patients, both the initial and follow-up PTX3 levels were consistently significantly higher in patients who died than in those who recovered (initial p = 0.004; follow-up P < 0.001). Conclusions The diagnostic and prognostic value of IL-6 was superior to those of PTX3 and PCT for sepsis and septic shock. Abstract Background This study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and septic shock diagnosed according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Methods Serum levels of IL-6, PTX3, and PCT were measured in 142 enrolled subjects (51 with sepsis, 46 with septic shock, and 45 as controls). Follow-up IL-6 and PTX3 levels were measured in patients with initial septic shock within 24 h of hospital discharge. Optimal cut-off values were determined for sepsis and septic shock, and prognostic values were evaluated. Results Serum IL-6 levels could discriminate sepsis (area under the curve [AUC], 0.83–0.94, P < 0.001; cut-off value, 52.60 pg/mL, 80.4% sensitivity, 88.9% specificity) from controls and could distinguish septic shock (AUC, 0.71–0.89; cut-off value, 348.92 pg/mL, 76.1% sensitivity, 78.4% specificity) from sepsis. Twenty-eight-day mortality was significantly higher in the group with high IL-6 (≥ 348.92 pg/mL) than in the group with low IL-6 (< 348.92 pg/mL) (P = 0.008). IL-6 was an independent risk factor for 28-day mortality among overall patients (hazard ratio, 1.0004; 95% confidence interval, 1.0003–1.0005; p = 0.024). In septic shock patients, both the initial and follow-up PTX3 levels were consistently significantly higher in patients who died than in those who recovered (initial p = 0.004; follow-up P < 0.001). Conclusions The diagnostic and prognostic value of IL-6 was superior to those of PTX3 and PCT for sepsis and septic shock. Background This study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and septic shock diagnosed according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Methods Serum levels of IL-6, PTX3, and PCT were measured in 142 enrolled subjects (51 with sepsis, 46 with septic shock, and 45 as controls). Follow-up IL-6 and PTX3 levels were measured in patients with initial septic shock within 24 h of hospital discharge. Optimal cut-off values were determined for sepsis and septic shock, and prognostic values were evaluated. Results Serum IL-6 levels could discriminate sepsis (area under the curve [AUC], 0.83-0.94, P < 0.001; cut-off value, 52.60 pg/mL, 80.4% sensitivity, 88.9% specificity) from controls and could distinguish septic shock (AUC, 0.71-0.89; cut-off value, 348.92 pg/mL, 76.1% sensitivity, 78.4% specificity) from sepsis. Twenty-eight-day mortality was significantly higher in the group with high IL-6 ([greater than or equai to] 348.92 pg/mL) than in the group with low IL-6 (< 348.92 pg/mL) (P = 0.008). IL-6 was an independent risk factor for 28-day mortality among overall patients (hazard ratio, 1.0004; 95% confidence interval, 1.0003-1.0005; p = 0.024). In septic shock patients, both the initial and follow-up PTX3 levels were consistently significantly higher in patients who died than in those who recovered (initial p = 0.004; follow-up P < 0.001). Conclusions The diagnostic and prognostic value of IL-6 was superior to those of PTX3 and PCT for sepsis and septic shock. Keywords: Interleukin-6, Pentraxin 3, Procalcitonin, Sepsis, Septic shock, Emergency department This study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and septic shock diagnosed according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Serum levels of IL-6, PTX3, and PCT were measured in 142 enrolled subjects (51 with sepsis, 46 with septic shock, and 45 as controls). Follow-up IL-6 and PTX3 levels were measured in patients with initial septic shock within 24 h of hospital discharge. Optimal cut-off values were determined for sepsis and septic shock, and prognostic values were evaluated. Serum IL-6 levels could discriminate sepsis (area under the curve [AUC], 0.83-0.94, P < 0.001; cut-off value, 52.60 pg/mL, 80.4% sensitivity, 88.9% specificity) from controls and could distinguish septic shock (AUC, 0.71-0.89; cut-off value, 348.92 pg/mL, 76.1% sensitivity, 78.4% specificity) from sepsis. Twenty-eight-day mortality was significantly higher in the group with high IL-6 (≥ 348.92 pg/mL) than in the group with low IL-6 (< 348.92 pg/mL) (P = 0.008). IL-6 was an independent risk factor for 28-day mortality among overall patients (hazard ratio, 1.0004; 95% confidence interval, 1.0003-1.0005; p = 0.024). In septic shock patients, both the initial and follow-up PTX3 levels were consistently significantly higher in patients who died than in those who recovered (initial p = 0.004; follow-up P < 0.001). The diagnostic and prognostic value of IL-6 was superior to those of PTX3 and PCT for sepsis and septic shock. This study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and septic shock diagnosed according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Serum levels of IL-6, PTX3, and PCT were measured in 142 enrolled subjects (51 with sepsis, 46 with septic shock, and 45 as controls). Follow-up IL-6 and PTX3 levels were measured in patients with initial septic shock within 24 h of hospital discharge. Optimal cut-off values were determined for sepsis and septic shock, and prognostic values were evaluated. Serum IL-6 levels could discriminate sepsis (area under the curve [AUC], 0.83-0.94, P < 0.001; cut-off value, 52.60 pg/mL, 80.4% sensitivity, 88.9% specificity) from controls and could distinguish septic shock (AUC, 0.71-0.89; cut-off value, 348.92 pg/mL, 76.1% sensitivity, 78.4% specificity) from sepsis. Twenty-eight-day mortality was significantly higher in the group with high IL-6 ([greater than or equai to] 348.92 pg/mL) than in the group with low IL-6 (< 348.92 pg/mL) (P = 0.008). IL-6 was an independent risk factor for 28-day mortality among overall patients (hazard ratio, 1.0004; 95% confidence interval, 1.0003-1.0005; p = 0.024). In septic shock patients, both the initial and follow-up PTX3 levels were consistently significantly higher in patients who died than in those who recovered (initial p = 0.004; follow-up P < 0.001). The diagnostic and prognostic value of IL-6 was superior to those of PTX3 and PCT for sepsis and septic shock. This study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and septic shock diagnosed according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).BACKGROUNDThis study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and septic shock diagnosed according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).Serum levels of IL-6, PTX3, and PCT were measured in 142 enrolled subjects (51 with sepsis, 46 with septic shock, and 45 as controls). Follow-up IL-6 and PTX3 levels were measured in patients with initial septic shock within 24 h of hospital discharge. Optimal cut-off values were determined for sepsis and septic shock, and prognostic values were evaluated.METHODSSerum levels of IL-6, PTX3, and PCT were measured in 142 enrolled subjects (51 with sepsis, 46 with septic shock, and 45 as controls). Follow-up IL-6 and PTX3 levels were measured in patients with initial septic shock within 24 h of hospital discharge. Optimal cut-off values were determined for sepsis and septic shock, and prognostic values were evaluated.Serum IL-6 levels could discriminate sepsis (area under the curve [AUC], 0.83-0.94, P < 0.001; cut-off value, 52.60 pg/mL, 80.4% sensitivity, 88.9% specificity) from controls and could distinguish septic shock (AUC, 0.71-0.89; cut-off value, 348.92 pg/mL, 76.1% sensitivity, 78.4% specificity) from sepsis. Twenty-eight-day mortality was significantly higher in the group with high IL-6 (≥ 348.92 pg/mL) than in the group with low IL-6 (< 348.92 pg/mL) (P = 0.008). IL-6 was an independent risk factor for 28-day mortality among overall patients (hazard ratio, 1.0004; 95% confidence interval, 1.0003-1.0005; p = 0.024). In septic shock patients, both the initial and follow-up PTX3 levels were consistently significantly higher in patients who died than in those who recovered (initial p = 0.004; follow-up P < 0.001).RESULTSSerum IL-6 levels could discriminate sepsis (area under the curve [AUC], 0.83-0.94, P < 0.001; cut-off value, 52.60 pg/mL, 80.4% sensitivity, 88.9% specificity) from controls and could distinguish septic shock (AUC, 0.71-0.89; cut-off value, 348.92 pg/mL, 76.1% sensitivity, 78.4% specificity) from sepsis. Twenty-eight-day mortality was significantly higher in the group with high IL-6 (≥ 348.92 pg/mL) than in the group with low IL-6 (< 348.92 pg/mL) (P = 0.008). IL-6 was an independent risk factor for 28-day mortality among overall patients (hazard ratio, 1.0004; 95% confidence interval, 1.0003-1.0005; p = 0.024). In septic shock patients, both the initial and follow-up PTX3 levels were consistently significantly higher in patients who died than in those who recovered (initial p = 0.004; follow-up P < 0.001).The diagnostic and prognostic value of IL-6 was superior to those of PTX3 and PCT for sepsis and septic shock.CONCLUSIONSThe diagnostic and prognostic value of IL-6 was superior to those of PTX3 and PCT for sepsis and septic shock.
ArticleNumber	968
Audience	Academic
Author	Park, Jong Hak Park, Dae Won Song, Juhyun Cho, Han-Jin Choi, Won Seok Moon, Sungwoo Seok, Hyeri
Author_xml	– sequence: 1 givenname: Juhyun surname: Song fullname: Song, Juhyun organization: Department of Emergency Medicine, Korea University Ansan Hospital – sequence: 2 givenname: Dae Won orcidid: 0000-0002-7653-686X surname: Park fullname: Park, Dae Won email: pugae1@hanmail.net organization: Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital – sequence: 3 givenname: Sungwoo surname: Moon fullname: Moon, Sungwoo organization: Department of Emergency Medicine, Korea University Ansan Hospital – sequence: 4 givenname: Han-Jin surname: Cho fullname: Cho, Han-Jin organization: Department of Emergency Medicine, Korea University Ansan Hospital – sequence: 5 givenname: Jong Hak surname: Park fullname: Park, Jong Hak organization: Department of Emergency Medicine, Korea University Ansan Hospital – sequence: 6 givenname: Hyeri surname: Seok fullname: Seok, Hyeri organization: Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital – sequence: 7 givenname: Won Seok surname: Choi fullname: Choi, Won Seok organization: Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31718563$$D View this record in MEDLINE/PubMed
BookMark	eNqNk8tq3DAUhk1JaS7tA3RTBN20EKe6-JpFIaS3QCDQtN0KWTp2lHgk15KH5P36YD2eyZRMKaF4YVn-_s-ydM5-suO8gyR5yegRY1XxLjBelXVKWZ1mBavS8kmyx7KSpVyIbOfBeDfZD-GaUlZWvH6W7ApWsiovxF7y64NVnfMhWk2UM2QY_eZxqfoJiG-JdRHGHqYb69LikAzg4qhurSPicJPRqtc2eoeTPSyhD0QtvOtIgCHYsKJwOFvDldc3ZFDRoiYcEzXHwwA62iUQ7dHt-x6Qj5O5I0prPxqLquhJvAJyuTKmghhorbPReheeJ09b1Qd4cX8_SL5_-vjt9Et6fvH57PTkPNVFJmJaAyilFeSNypUooOba8Mq0bZ6XirOWFapBhDGtjalpJgxkTU5FBrkoeFmLg-Rs7TVeXcthtAs13kmvrFxN-LGTasSf7EHW3GSCF7lq2yLjGcUvNjQvGs4akbO2Qtf7tWuYmgUYvdrUfku6_cbZK9n5pSyqnJeCouDNvWD0PycIUS5s0ND3yoGfguSCZTznlApEX6_RTuHSrGs9GvWMy5OClgJXKGbq6B8UXgYWFg8G9xvntwJvtwLz4cFt7NQUgjy7_Pr_7MWPbfbVw635syebqkWgXAMaSyeM0EosPjWXAq7Y9pJROfeHXPeHxP6Qc3_IEpPsr-RG_liGrzMBWdfBKK_9NDostEdCvwGUgyTJ
CitedBy_id	crossref_primary_10_1177_17534259231205959 crossref_primary_10_1080_14737159_2025_2505537 crossref_primary_10_1093_jacamr_dlae100 crossref_primary_10_1002_smll_202409042 crossref_primary_10_3390_diagnostics12020509 crossref_primary_10_3390_biom15030407 crossref_primary_10_12688_f1000research_163800_1 crossref_primary_10_1016_j_ajem_2020_12_076 crossref_primary_10_3389_fimmu_2021_741268 crossref_primary_10_1016_j_jim_2023_113570 crossref_primary_10_1016_j_ejrad_2023_111075 crossref_primary_10_1590_1806_9282_20220940 crossref_primary_10_1055_a_2435_1940 crossref_primary_10_1038_s41598_024_80575_z crossref_primary_10_7717_peerj_12997 crossref_primary_10_1097_SHK_0000000000002055 crossref_primary_10_3892_etm_2024_12416 crossref_primary_10_1371_journal_pgph_0004429 crossref_primary_10_3390_v14112582 crossref_primary_10_3389_fmed_2024_1328719 crossref_primary_10_1097_CCE_0000000000000414 crossref_primary_10_3390_ijms241210139 crossref_primary_10_2147_RMHP_S268238 crossref_primary_10_3390_jcm13195919 crossref_primary_10_3389_fmed_2024_1410014 crossref_primary_10_1080_00365513_2021_1969592 crossref_primary_10_1002_jcla_24838 crossref_primary_10_1021_acsabm_5c00545 crossref_primary_10_3390_jcm14155415 crossref_primary_10_3389_fimmu_2024_1498974 crossref_primary_10_1038_s41598_024_53756_z crossref_primary_10_2147_JIR_S361466 crossref_primary_10_1089_jir_2020_0135 crossref_primary_10_3389_fimmu_2022_979232 crossref_primary_10_1002_mco2_70109 crossref_primary_10_1007_s11739_025_04081_4 crossref_primary_10_1097_MD_0000000000042950 crossref_primary_10_1016_j_arbres_2022_01_010 crossref_primary_10_1371_journal_pone_0243849 crossref_primary_10_1186_s41512_023_00152_2 crossref_primary_10_1007_s10456_024_09916_w crossref_primary_10_1093_cei_uxae019 crossref_primary_10_1177_1753466620937175 crossref_primary_10_1186_s13054_023_04713_1 crossref_primary_10_3390_medicina61030468 crossref_primary_10_3389_fimmu_2020_571992 crossref_primary_10_1080_14656566_2023_2213828 crossref_primary_10_1016_j_snr_2025_100382 crossref_primary_10_3390_ijms24065363 crossref_primary_10_3390_ijms25137396 crossref_primary_10_1016_j_thromres_2025_109479 crossref_primary_10_3389_fmicb_2022_965518 crossref_primary_10_13181_mji_oa_202943 crossref_primary_10_1186_s12879_021_06145_0 crossref_primary_10_1016_j_clinbiochem_2025_110878 crossref_primary_10_1016_j_jemermed_2024_05_005 crossref_primary_10_1177_07487304221092727 crossref_primary_10_1038_s41598_024_51414_y crossref_primary_10_1016_j_jormas_2022_05_017 crossref_primary_10_1016_j_trac_2024_117615 crossref_primary_10_5498_wjp_v15_i4_102763 crossref_primary_10_1002_admt_202400395 crossref_primary_10_1097_SHK_0000000000001965 crossref_primary_10_1097_SHK_0000000000002495 crossref_primary_10_1016_j_resuscitation_2024_110382 crossref_primary_10_1016_j_cegh_2021_100727 crossref_primary_10_3390_cells14060441 crossref_primary_10_3390_jcm13195678 crossref_primary_10_5005_jp_journals_10089_0187 crossref_primary_10_1177_17562872231151852 crossref_primary_10_1016_j_molimm_2023_10_006 crossref_primary_10_1080_03007995_2024_2362274 crossref_primary_10_1016_j_intimp_2021_107421 crossref_primary_10_12998_wjcc_v9_i25_7405 crossref_primary_10_1186_s40560_025_00775_1 crossref_primary_10_2147_JIR_S523124 crossref_primary_10_3390_ijms241210175 crossref_primary_10_5812_aapm_111272 crossref_primary_10_1007_s10096_022_04517_1 crossref_primary_10_1080_03007995_2022_2033049 crossref_primary_10_1080_10799893_2022_2097264 crossref_primary_10_1097_MD_0000000000020495 crossref_primary_10_1097_SHK_0000000000002363 crossref_primary_10_2147_IDR_S304952 crossref_primary_10_1016_j_ejim_2023_08_005 crossref_primary_10_3389_fimmu_2023_1200939 crossref_primary_10_5847_wjem_j_1920_8642_2022_095 crossref_primary_10_3390_biomedicines8110494 crossref_primary_10_1097_MD_0000000000042115 crossref_primary_10_1038_s41540_024_00473_y crossref_primary_10_3389_fbioe_2022_796996 crossref_primary_10_3390_biom15030312 crossref_primary_10_1016_j_joms_2024_09_005 crossref_primary_10_1007_s10143_022_01827_y crossref_primary_10_1007_s10238_023_01114_0 crossref_primary_10_1371_journal_pone_0278708 crossref_primary_10_1186_s12893_025_03000_w crossref_primary_10_1007_s00240_022_01366_7 crossref_primary_10_3390_biomedicines9030311 crossref_primary_10_1007_s00216_025_06011_x crossref_primary_10_1016_j_cca_2022_02_007 crossref_primary_10_1016_j_ajog_2022_04_015 crossref_primary_10_2147_IDR_S384351 crossref_primary_10_1007_s10047_025_01523_w crossref_primary_10_61751_bmbr_3_2024_50 crossref_primary_10_1016_j_humgen_2022_201124 crossref_primary_10_1186_s12894_024_01502_y crossref_primary_10_3390_ijms25169010 crossref_primary_10_1093_labmed_lmae112 crossref_primary_10_3389_fimmu_2021_639735 crossref_primary_10_1128_cmr_00078_24 crossref_primary_10_2147_JMDH_S422359 crossref_primary_10_1186_s12879_021_06999_4 crossref_primary_10_1186_s40635_021_00400_z crossref_primary_10_1186_s10020_025_01226_1 crossref_primary_10_1186_s12879_025_11282_x crossref_primary_10_3390_membranes12080811 crossref_primary_10_3390_children8070563 crossref_primary_10_5604_01_3001_0054_7916 crossref_primary_10_1017_neu_2023_11 crossref_primary_10_1111_ejh_14264 crossref_primary_10_1016_j_jaci_2020_07_001 crossref_primary_10_1016_j_medcle_2023_01_022 crossref_primary_10_1080_1750743X_2024_2370180 crossref_primary_10_5937_afmnai42_50136 crossref_primary_10_1007_s12288_021_01411_2 crossref_primary_10_1097_MD_0000000000034295 crossref_primary_10_1016_j_ultrasmedbio_2023_03_008 crossref_primary_10_1155_2021_8583118 crossref_primary_10_3390_toxins12090545 crossref_primary_10_1016_j_sapharm_2022_07_004 crossref_primary_10_1016_j_medcli_2023_01_022 crossref_primary_10_1097_MD_0000000000021893 crossref_primary_10_2174_03666220817145707 crossref_primary_10_2147_IJGM_S402586 crossref_primary_10_1097_CCE_0000000000000387 crossref_primary_10_1111_ped_14882 crossref_primary_10_1016_j_bcp_2021_114822 crossref_primary_10_5005_jp_journals_10071_24754 crossref_primary_10_3390_v17070997 crossref_primary_10_3390_ijms24021583 crossref_primary_10_1186_s12879_021_06422_y crossref_primary_10_3389_fmed_2024_1360197 crossref_primary_10_3390_pathogens12111293 crossref_primary_10_46879_ukroj_3_2024_299_320 crossref_primary_10_1007_s10489_024_05783_6 crossref_primary_10_1016_j_ric_2025_100009 crossref_primary_10_1371_journal_pbio_3000970 crossref_primary_10_1016_j_cca_2023_117352 crossref_primary_10_3390_diagnostics11101906 crossref_primary_10_3389_fimmu_2022_907461 crossref_primary_10_2147_JIR_S521684 crossref_primary_10_1007_s10238_024_01450_9 crossref_primary_10_1016_j_bios_2024_116202 crossref_primary_10_1093_burnst_tkad023 crossref_primary_10_4103_njcp_njcp_615_23 crossref_primary_10_1186_s12967_020_02620_5 crossref_primary_10_3389_fmed_2025_1560737 crossref_primary_10_1016_j_imlet_2025_107072 crossref_primary_10_1016_j_heliyon_2022_e11409 crossref_primary_10_1186_s12873_021_00461_z crossref_primary_10_3390_genes13020209 crossref_primary_10_1007_s40121_022_00622_y crossref_primary_10_1007_s11908_021_00747_0 crossref_primary_10_3390_metabo15030204 crossref_primary_10_1007_s10787_025_01649_6 crossref_primary_10_3389_fimmu_2025_1641285 crossref_primary_10_1016_j_intimp_2021_107701 crossref_primary_10_1371_journal_pone_0257177 crossref_primary_10_1002_jmv_26654 crossref_primary_10_1093_jleuko_qiae121 crossref_primary_10_3389_fphar_2023_1166923 crossref_primary_10_1155_2022_1864776 crossref_primary_10_1016_j_arbres_2022_01_003 crossref_primary_10_1371_journal_pone_0263968 crossref_primary_10_2147_JIR_S338383 crossref_primary_10_3389_fcvm_2022_899583 crossref_primary_10_1097_SHK_0000000000002402 crossref_primary_10_3390_jcm11247324 crossref_primary_10_1186_s13054_025_05318_6 crossref_primary_10_1016_j_jceh_2021_11_008 crossref_primary_10_3389_fimmu_2025_1520848 crossref_primary_10_3389_fpubh_2023_1181880 crossref_primary_10_1186_s40001_025_02369_x crossref_primary_10_1016_j_prp_2024_155548 crossref_primary_10_3390_cancers16081512 crossref_primary_10_7717_peerj_19689 crossref_primary_10_1016_j_jviromet_2021_114224 crossref_primary_10_1038_s41598_025_15784_1 crossref_primary_10_3389_fcimb_2023_1101428 crossref_primary_10_3389_fimmu_2025_1578590 crossref_primary_10_7717_peerj_18471 crossref_primary_10_1371_journal_pone_0256784 crossref_primary_10_1007_s00109_020_01996_7 crossref_primary_10_1016_j_resp_2022_104002 crossref_primary_10_1016_j_talanta_2023_124284 crossref_primary_10_1097_HC9_0000000000000539 crossref_primary_10_1186_s12868_022_00770_4 crossref_primary_10_3390_ijms241512376 crossref_primary_10_1161_CIRCRESAHA_123_323662 crossref_primary_10_1186_s12865_024_00679_z
Cites_doi	10.1155/2014/547818 10.1016/j.diagmicrobio.2012.12.011 10.1097/00003246-198510000-00009 10.3109/00365548.2011.600325 10.3349/ymj.2017.58.2.370 10.1001/jama.2016.0287 10.1111/eci.12704 10.1097/SHK.0b013e31819716fa 10.1056/NEJMra1208623 10.1186/s12879-017-2606-3 10.1007/BF01709751 10.1001/jama.2016.0289 10.1111/joim.12294 10.1093/jac/dkq523 10.1093/infdis/172.1.296 10.1007/s00134-010-1752-5 10.1001/jama.2017.0059 10.1111/j.1469-0691.2004.01044.x 10.1515/CCLM.2009.110 10.1186/cc7918 10.1002/bjs.1800810914 10.1371/journal.pone.0053661 10.1016/j.cyto.2016.08.033 10.1007/s00134-002-1416-1 10.1097/SHK.0000000000000616 10.1007/s10875-007-9126-7 10.1371/journal.pone.0017653 10.1186/s13054-014-0507-z 10.1086/317499 10.1097/CCM.0000000000002255 10.1179/acb.2010.037 10.1007/s00134-009-1402-y 10.1016/j.jcrc.2016.01.002 10.1164/ajrccm.164.3.2009052 10.1016/j.amjms.2017.01.003 10.18632/oncotarget.23701 10.1146/annurev.immunol.23.021704.115756 10.1074/mcp.M114.039446
ContentType	Journal Article
Copyright	The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd.
Copyright_xml	– notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd.
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 7X8 5PM DOA
DOI	10.1186/s12879-019-4618-7
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1471-2334
EndPage	11
ExternalDocumentID	oai_doaj_org_article_92d43265aff64240a5ab056b21b351f8 PMC6852730 A607364233 31718563 10_1186_s12879_019_4618_7
Genre	Journal Article
GrantInformation_xml	– fundername: Korea University Ansan Hospital grantid: O1700641; K1722241 – fundername: Korea University Ansan Hospital grantid: O1700641 – fundername: Korea University Ansan Hospital grantid: K1722241 – fundername: ; grantid: O1700641; K1722241
GroupedDBID	--- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR IOV ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7X8 5PM
ID	FETCH-LOGICAL-c643t-9eeaacae5ba5a36e92cd28dff557a21f16abeea11ccdd9043de4b5034e5362793
IEDL.DBID	DOA
ISICitedReferencesCount	240
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000497667000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1471-2334
IngestDate	Fri Oct 03 12:50:56 EDT 2025 Tue Nov 04 01:48:30 EST 2025 Fri Sep 05 09:22:40 EDT 2025 Tue Nov 11 10:23:32 EST 2025 Tue Nov 04 17:55:55 EST 2025 Thu Nov 13 15:23:14 EST 2025 Thu Nov 13 15:53:11 EST 2025 Thu Jan 02 22:59:57 EST 2025 Sat Nov 29 03:14:03 EST 2025 Tue Nov 18 22:29:37 EST 2025 Sat Sep 06 07:26:46 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Sepsis Septic shock Emergency department Pentraxin 3 Procalcitonin Interleukin-6
Language	English
License	Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c643t-9eeaacae5ba5a36e92cd28dff557a21f16abeea11ccdd9043de4b5034e5362793
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0002-7653-686X
OpenAccessLink	https://doaj.org/article/92d43265aff64240a5ab056b21b351f8
PMID	31718563
PQID	2314252003
PQPubID	23479
PageCount	11
ParticipantIDs	doaj_primary_oai_doaj_org_article_92d43265aff64240a5ab056b21b351f8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6852730 proquest_miscellaneous_2314252003 gale_infotracmisc_A607364233 gale_infotracacademiconefile_A607364233 gale_incontextgauss_ISR_A607364233 gale_incontextgauss_IOV_A607364233 pubmed_primary_31718563 crossref_citationtrail_10_1186_s12879_019_4618_7 crossref_primary_10_1186_s12879_019_4618_7 springer_journals_10_1186_s12879_019_4618_7
PublicationCentury	2000
PublicationDate	2019-11-12
PublicationDateYYYYMMDD	2019-11-12
PublicationDate_xml	– month: 11 year: 2019 text: 2019-11-12 day: 12
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	BMC infectious diseases
PublicationTitleAbbrev	BMC Infect Dis
PublicationTitleAlternate	BMC Infect Dis
PublicationYear	2019
Publisher	BioMed Central BioMed Central Ltd BMC
Publisher_xml	– name: BioMed Central – name: BioMed Central Ltd – name: BMC
References	C Hu (4618_CR28) 2018; 9 WA Knaus (4618_CR33) 1985; 13 C Henriquez-Camacho (4618_CR11) 2014; 2014 S Liu (4618_CR25) 2014; 2014 JL Vincent (4618_CR34) 1996; 22 H Jie (4618_CR27) 2017; 353 4618_CR10 T Mauri (4618_CR24) 2010; 36 D De Backer (4618_CR5) 2017; 317 M Shankar-Hari (4618_CR4) 2016; 315 P Póvoa (4618_CR8) 2005; 11 A Spittler (4618_CR13) 2000; 31 S Hamed (4618_CR32) 2017; 17 L Ma (4618_CR12) 2016; 88 BM Biron (4618_CR6) 2015; 10 DW Jekarl (4618_CR19) 2013; 75 MB Mat-Nor (4618_CR36) 2016; 33 B Gårdlund (4618_CR15) 1995; 172 M Singer (4618_CR1) 2016; 315 RT Patel (4618_CR14) 1994; 81 M Behnes (4618_CR35) 2014; 18 YT Lee (4618_CR31) 2018; 76 P Caironi (4618_CR30) 2017; 47 HM Soliman (4618_CR43) 2010; 65 S Hamed (4618_CR39) 2018; 64 K Yamasaki (4618_CR40) 2009; 47 A Mantovani (4618_CR21) 2008; 28 H Khosravani (4618_CR42) 2009; 13 W Takahashi (4618_CR20) 2016; 46 SB Kim (4618_CR26) 2017; 58 A Nakamura (4618_CR9) 2009; 31 S Harbarth (4618_CR16) 2001; 164 V Miguel-Bayarri (4618_CR18) 2012; 36 S Bastrup-Birk (4618_CR38) 2015; 277 R Uusitalo-Seppälä (4618_CR23) 2013; 8 C Garlanda (4618_CR22) 2005; 23 V Pettilä (4618_CR17) 2002; 28 R Uusitalo-Seppälä (4618_CR37) 2011; 43 R Huttunen (4618_CR41) 2011; 6 J Silvestre (4618_CR7) 2009; 35 A Rhodes (4618_CR2) 2017; 45 DC Angus (4618_CR3) 2013; 369 F Cuello (4618_CR29) 2014; 13
References_xml	– volume: 2014 start-page: 547818 year: 2014 ident: 4618_CR11 publication-title: Biomed Res Int doi: 10.1155/2014/547818 – volume: 75 start-page: 342 issue: 4 year: 2013 ident: 4618_CR19 publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2012.12.011 – volume: 13 start-page: 818 issue: 10 year: 1985 ident: 4618_CR33 publication-title: Crit Care Med doi: 10.1097/00003246-198510000-00009 – volume: 2014 start-page: 421429 year: 2014 ident: 4618_CR25 publication-title: Mediat Inflamm – volume: 43 start-page: 883 issue: 11–12 year: 2011 ident: 4618_CR37 publication-title: Scand J Infect Dis doi: 10.3109/00365548.2011.600325 – volume: 58 start-page: 370 issue: 2 year: 2017 ident: 4618_CR26 publication-title: Yonsei Med J doi: 10.3349/ymj.2017.58.2.370 – volume: 315 start-page: 801 issue: 8 year: 2016 ident: 4618_CR1 publication-title: JAMA. doi: 10.1001/jama.2016.0287 – volume: 47 start-page: 73 issue: 1 year: 2017 ident: 4618_CR30 publication-title: Eur J Clin Investig doi: 10.1111/eci.12704 – volume: 31 start-page: 586 issue: 6 year: 2009 ident: 4618_CR9 publication-title: Shock. doi: 10.1097/SHK.0b013e31819716fa – volume: 369 start-page: 840 issue: 9 year: 2013 ident: 4618_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMra1208623 – volume: 64 start-page: 999 issue: 6 year: 2018 ident: 4618_CR39 publication-title: Clin Lab – volume: 17 start-page: 554 issue: 1 year: 2017 ident: 4618_CR32 publication-title: BMC Infect Dis doi: 10.1186/s12879-017-2606-3 – volume: 22 start-page: 707 issue: 7 year: 1996 ident: 4618_CR34 publication-title: Intensive Care Med doi: 10.1007/BF01709751 – volume: 10 start-page: 7 issue: Suppl 4 year: 2015 ident: 4618_CR6 publication-title: Biomark Insights – volume: 315 start-page: 775 issue: 8 year: 2016 ident: 4618_CR4 publication-title: JAMA. doi: 10.1001/jama.2016.0289 – volume: 277 start-page: 562 issue: 5 year: 2015 ident: 4618_CR38 publication-title: J Intern Med doi: 10.1111/joim.12294 – ident: 4618_CR10 doi: 10.1093/jac/dkq523 – volume: 172 start-page: 296 issue: 1 year: 1995 ident: 4618_CR15 publication-title: J Infect Dis doi: 10.1093/infdis/172.1.296 – volume: 36 start-page: 621 issue: 4 year: 2010 ident: 4618_CR24 publication-title: Intensive Care Med doi: 10.1007/s00134-010-1752-5 – volume: 317 start-page: 807 issue: 8 year: 2017 ident: 4618_CR5 publication-title: JAMA. doi: 10.1001/jama.2017.0059 – volume: 11 start-page: 101 issue: 2 year: 2005 ident: 4618_CR8 publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2004.01044.x – volume: 47 start-page: 471 issue: 4 year: 2009 ident: 4618_CR40 publication-title: Clin Chem Lab Med doi: 10.1515/CCLM.2009.110 – volume: 13 start-page: R90 issue: 3 year: 2009 ident: 4618_CR42 publication-title: Crit Care doi: 10.1186/cc7918 – volume: 81 start-page: 1306 issue: 9 year: 1994 ident: 4618_CR14 publication-title: Br J Surg doi: 10.1002/bjs.1800810914 – volume: 8 issue: 1 year: 2013 ident: 4618_CR23 publication-title: PLoS One doi: 10.1371/journal.pone.0053661 – volume: 88 start-page: 126 year: 2016 ident: 4618_CR12 publication-title: Cytokine. doi: 10.1016/j.cyto.2016.08.033 – volume: 28 start-page: 1220 issue: 9 year: 2002 ident: 4618_CR17 publication-title: Intensive Care Med doi: 10.1007/s00134-002-1416-1 – volume: 46 start-page: 254 issue: 3 year: 2016 ident: 4618_CR20 publication-title: Shock. doi: 10.1097/SHK.0000000000000616 – volume: 28 start-page: 1 issue: 1 year: 2008 ident: 4618_CR21 publication-title: J Clin Immunol doi: 10.1007/s10875-007-9126-7 – volume: 76 start-page: 1 issue: 1 year: 2018 ident: 4618_CR31 publication-title: J Inf Secur – volume: 6 issue: 3 year: 2011 ident: 4618_CR41 publication-title: PLoS One doi: 10.1371/journal.pone.0017653 – volume: 18 start-page: 507 issue: 5 year: 2014 ident: 4618_CR35 publication-title: Crit Care doi: 10.1186/s13054-014-0507-z – volume: 31 start-page: 1338 issue: 6 year: 2000 ident: 4618_CR13 publication-title: Clin Infect Dis doi: 10.1086/317499 – volume: 45 start-page: 486 issue: 3 year: 2017 ident: 4618_CR2 publication-title: Crit Care Med doi: 10.1097/CCM.0000000000002255 – volume: 65 start-page: 176 issue: 3 year: 2010 ident: 4618_CR43 publication-title: Acta Clin Belg doi: 10.1179/acb.2010.037 – volume: 35 start-page: 909 issue: 5 year: 2009 ident: 4618_CR7 publication-title: Intensive Care Med doi: 10.1007/s00134-009-1402-y – volume: 33 start-page: 245 year: 2016 ident: 4618_CR36 publication-title: J Crit Care doi: 10.1016/j.jcrc.2016.01.002 – volume: 164 start-page: 396 issue: 3 year: 2001 ident: 4618_CR16 publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.164.3.2009052 – volume: 353 start-page: 242 issue: 3 year: 2017 ident: 4618_CR27 publication-title: Am J Med Sci doi: 10.1016/j.amjms.2017.01.003 – volume: 9 start-page: 5125 issue: 4 year: 2018 ident: 4618_CR28 publication-title: Oncotarget. doi: 10.18632/oncotarget.23701 – volume: 36 start-page: 556 issue: 8 year: 2012 ident: 4618_CR18 publication-title: Med Int – volume: 23 start-page: 337 year: 2005 ident: 4618_CR22 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.23.021704.115756 – volume: 13 start-page: 2545 issue: 10 year: 2014 ident: 4618_CR29 publication-title: Mol Cell Proteomics doi: 10.1074/mcp.M114.039446
SSID	ssj0017829
Score	2.6436799
Snippet	Background This study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and septic... This study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and septic shock... Background This study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and septic... Abstract Background This study investigated the clinical value of interleukin-6 (IL-6), pentraxin 3 (PTX3), and procalcitonin (PCT) in patients with sepsis and...
SourceID	doaj pubmedcentral proquest gale pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	968
SubjectTerms	Adult Aged Aged, 80 and over Area Under Curve Bacterial and fungal diseases Biomarkers - blood C-Reactive Protein - analysis Case-Control Studies Emergency department Female Hospital admission and discharge Humans Infection Infectious Diseases Interleukin-6 Interleukin-6 - blood Interleukins Internal Medicine Male Medical Microbiology Medical research Medicine Medicine & Public Health Middle Aged Mortality Parasitology Pentraxin 3 Procalcitonin Procalcitonin - blood Prognosis Research Article Risk Factors ROC Curve Sensitivity and Specificity Sepsis Sepsis - diagnosis Sepsis - mortality Sepsis - pathology Septic shock Serum Amyloid P-Component - analysis Severity of Illness Index Shock Shock, Septic - diagnosis Shock, Septic - mortality Shock, Septic - pathology Tropical Medicine
SummonAdditionalLinks	– databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELWgIMQL90ugIIOQkKARca4Ob-VSwQMFdaHqm-X40kasktV6F_GBfBgzjrMihSLB48bjaB17zow1x8eEPEmM0mnNTFxXso5zbUwsubIxM3mTp6kpmGr8ZRPV_j4_Oqo_hXPcbmS7jyVJj9TerXn5wgGSVsjtgVeWjMfVeXIBoh1HbzyYHW5KBxDy6lC-_GO3SQDyOv2_o_Ev4eg0VfJUvdSHob2r_zWAa-RKyDrp7rBMrpNzprtBLn0IdfWb5MebgXEHzVR2miJrK_xENXBDe0tRWGI5N-uvbReXO3Th_-r3tqPZztgH5lsBQnTwcI5kJEf9XUbUmYVrnbdyyKJR1J0ADtMg6upeUondx1OfNPDn5wbsUf6WSoWbZBgsXfUUUlY682-MM6qNbbuBdnaLfNl7-_n1uzjc7xAryINWcW2MlEqaopGFzEpTp7BuuLa2KCqZMstK2YAJY0ppXSd5pmEBFUmWmwLCLgDLbbLV9Z25SyjWTy3kmizDsq-tuZaJLmGv12gueVJGJBknXaggfo53cMyF3wTxUgyzI2B2BM6OqCLybNNlMSh__M34Fa6kjSGKdvsH_fJYBAwQdapzyJYLaS3s-vIERt1A_tmkrMkKZnlEHuM6FCjL0SHv51iunRPvPx6K3RKgGDpl2VlGs4OJ0dNgZHsYppLhrAV8LJT7mlhuTywBXNSk-dHoEwKbkJHXmX7tBOwLAO6R2hiRO4OPbEYPOSmkgSW0VBPvmXyeaUvXnnht85KjImASkeejD4kAqu7sr3_vn6zvk8spOiFyOdNtsrVars0DclF9W7Vu-dCDyU99xnRt priority: 102 providerName: Springer Nature
Title	Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions
URI	https://link.springer.com/article/10.1186/s12879-019-4618-7 https://www.ncbi.nlm.nih.gov/pubmed/31718563 https://www.proquest.com/docview/2314252003 https://pubmed.ncbi.nlm.nih.gov/PMC6852730 https://doaj.org/article/92d43265aff64240a5ab056b21b351f8
Volume	19
WOSCitedRecordID	wos000497667000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (ProQuest) customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: 8C1 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELagIMQF8SyBEhmEhARddb3v5daWVvTQECVQlZPl9YOuiDZRnCB-ID-MGa836hYVLlxW8nqcrO3xzFjz-TMhr0MtVVQyHZS5KINEaR2IQpqA6aRKokinTFbusol8NCrOz8vxpau-EBPW0gO3A7dXRiqBECMVxkConIQiFRU47SpiVZwy4475QtTTbaZ8_gD8XulzmKzI9ixY4RxxQfA5GSuCvOeFHFn_nyb5kk-6ipe8kjR1vuj4Prnng0i63378A3JDNw_JnVOfJn9Efn1oAXRQTUWjKIKwfBHJvTWdG4o8EcuZXn-vmyDbpQv3pz_rhsa7XRuYPgkLvoGXM8QWWequJqJWL2xtnZRFUIyk9gLMKvUcrfY9Fdi8O8RJPRx-pkEe2WypkLjnha7R1ZxCBEqn7heDmCpt6qZFkT0mX46PPh9-DPx1DYGEsGYVlFoLIYVOK5ijONNlBGpQKGPSNBcRMywTFYgwJqVSZZjECvQhDeNEp-BFwU48IVvNvNFPCcV0qIHQkcWYxTVloUSoMti6VaoQRZgNSNhNH5eeyxyv1Jhxt6cpMt7OOIcZ5zjjPB-Qt5smi5bI42_CB6gTG0Hk4HYvQDO510z-L80ckFeoURxZNhqE8XwTa2v5yaczvp-BZYVGcXyd0HTSE3rjhcwcuimFPzoBg4XsXT3JnZ4k2ArZq37ZaTfHKgTYNXq-thzCfLDeiFQckO1W2ze9hxAToroMavLeOugNT7-mqS8cVXlWIMFfOCDvuhXDvY2014_-s_8x-s_J3QjXOyI2ox2ytVqu9QtyW_5Y1XY5JDfz89w9C3gWh2xIbh0cjcaTobMjUBqfnI6_QmkyPfsNR0V21w
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELWgIOCF-2WhgEFISNCIOPfwVi5VK9oFdduqb5bjSxuxSlbrXcQH8mHMOM6KFIoEjxuPo3XsOTPWHB8T8iLUUkUl00GZizJIlNaBKKQJmE6qJIp0ymTlLpvIx-Pi-Lj84s9x257t3pckHVI7ty6yNxaQNEduD7wyY0WQXySXEghYyOPbnxytSgcQ8kpfvvxjt0EAcjr9v6PxL-HoLFXyTL3UhaGtG_81gJvkus866Wa3TG6RC7q5Ta7s-br6HfLjQ8e4g2YqGkWRteV_ohq4pq2hKCwxn-rl17oJsg06c3_1e93QeKPvA_MtASEaeDhFMpKl7i4javXM1tZZWWTRSGpPAYepF3W1b6nA7v2pT-r581MN9ih_S4XETTIMli5aCikrnbg3BjFV2tRNRzu7Sw63Ph683w78_Q6BhDxoEZRaCyGFTiuRijjTZQTrplDGpGkuImZYJiowYUxKpcowiRUsoDSME51C2AVguUfWmrbRDwjF-qmBXJPFWPY1ZaFEqDLY61WqEEWYjUjYTzqXXvwc7-CYcrcJKjLezQ6H2eE4OzwfkVerLrNO-eNvxu9wJa0MUbTbPWjnJ9xjAC8jlUC2nApjYNeXhDDqCvLPKmJVnDJTjMhzXIccZTka5P2ciKW1fOfzEd_MAIqhUxyfZzTZHxi99EamhWFK4c9awMdCua-B5frAEsBFDpqf9T7BsQkZeY1ul5bDvgDgHqmNI3K_85HV6CEnhTQwg5Z84D2DzzNsaepTp22eFagIGI7I696HuAdVe_7Xf_hP1k_J1e2DvV2-uzP-9Ihci9AhkdcZrZO1xXypH5PL8tuitvMnDlh-AvEId1E
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZbxMxELagoIoX7iNQwCAkJOiqex-8FUpEBYSK0KpvltdHuyLyRnGC-IH8MGa83ogtFAnxmPV4FXtnxjOaz98Q8ixUQsZVpIKq4FWQSqUCXgodRCqt0zhWWSRq12yimEzK4-PqwPc5tT3avS9JdncakKXJLHfmUncmXuY7FrxqgTgfeH0elUFxkVxKsWcQpuvTo3UZAY6_ypcy_zhtcBg5zv7fPfMvR9NZ2OSZ2qk7ksbX_nsx18lVH43S3U59bpALytwkmx99vf0W-bHXIfFgmHIjKaK5_E9kCVe01RQJJxYztframCDfpnP3t783hibb_RzQAwGew8DDGYKULHU9jqhVc9tYJ2URXSOoPQX_TD3Zq31FOU7vb4NSj6ufKZBHWlzKBSbPsHC6bCmEsnTq3hgkVCrdmA6Odpscjt9-efMu8H0fAgHx0TKolOJccJXVPONJrqoY9KmUWmdZweNIRzmvQSSKhJCyCtNEgmJlYZKqDI5jcDh3yIZpjbpHKNZVNcSgUYLlYF2VkocyhxywliUvw3xEwl4BmPCk6NibY8ZcclTmrPs6DL4Ow6_DihF5sZ4y7xhB_ib8GrVqLYhk3u5Buzhh3jewKpYpRNEZ1xqywTSEVdcQl9ZxVCdZpMsReYo6yZCuwyAe6ISvrGX7n47Ybg4uGiYlyXlC088DoedeSLewTMH9HQzYLKQBG0huDSTB6YjB8JPePhgOIVLPqHZlGeQLcAwg5HFE7nb2sl49xKoQHuYwUgwsabA9wxHTnDrO87xEpsBwRF729sS8s7Xn7_79f5J-TDYP9sbsw_7k_QNyJUZ7RLhnvEU2louVekgui2_Lxi4eOR_zE3jxgDU
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diagnostic+and+prognostic+value+of+interleukin-6%2C+pentraxin+3%2C+and+procalcitonin+levels+among+sepsis+and+septic+shock+patients%3A+a+prospective+controlled+study+according+to+the+Sepsis-3+definitions&rft.jtitle=BMC+infectious+diseases&rft.au=Song%2C+Juhyun&rft.au=Park%2C+Dae+Won&rft.au=Moon%2C+Sungwoo&rft.au=Cho%2C+Han-Jin&rft.date=2019-11-12&rft.issn=1471-2334&rft.eissn=1471-2334&rft.volume=19&rft.issue=1&rft_id=info:doi/10.1186%2Fs12879-019-4618-7&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12879_019_4618_7
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon